Jian L Campian Selected Research

Aftercare (After-Treatment)

3/2021	The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
4/2019	Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jian L Campian Research Topics

Disease

23	Glioblastoma (Glioblastoma Multiforme) 05/2024 - 01/2016
20	Neoplasms (Cancer) 05/2024 - 09/2015
9	Glioma (Gliomas) 03/2023 - 08/2015
6	Lymphopenia (Lymphocytopenia) 01/2022 - 08/2015
4	Astrocytoma (Pilocytic Astrocytoma) 01/2021 - 11/2017
3	Acoustic Neuroma (Acoustic Neurinoma) 01/2023 - 12/2019
2	Brain Neoplasms (Brain Tumor) 01/2024 - 01/2022
2	Schwannomatosis 01/2023 - 01/2023
2	Disease Progression 01/2023 - 03/2021
2	Hearing Loss (Hearing Impairment) 01/2023 - 12/2019
2	Oligodendroglioma 01/2021 - 01/2018
1	Hepatitis 02/2024
1	Melanoma (Melanoma, Malignant) 02/2024
1	Neurofibromatoses (Neurofibromatosis) 01/2023
1	Hypophysitis 01/2023
1	Carcinoma (Carcinomatosis) 01/2023
1	Central Nervous System Diseases (CNS Diseases) 11/2022
1	Aplastic Anemia (Anemia, Hypoplastic) 09/2020
1	Neurofibromatosis 2 (Neurofibromatosis Type II) 12/2019
1	Edema (Dropsy) 05/2019
1	Triple Negative Breast Neoplasms 04/2019
1	Necrosis 01/2018
1	Meningioma (Meningiomas) 01/2018
1	Neurologic Manifestations (Neurological Manifestations) 10/2017

Drug/Important Bio-Agent (IBA)

12	Temozolomide (Temodar)FDA LinkGeneric 05/2022 - 08/2015
7	Bevacizumab (Avastin)FDA Link 01/2023 - 01/2018
4	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 03/2023 - 01/2018
4	Biomarkers (Surrogate Marker)IBA 03/2023 - 12/2019
4	VaccinesIBA 01/2023 - 01/2018
3	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2022
3	Protons (Proton)IBA 02/2024 - 01/2018
3	Disulfiram (Antabuse)FDA Link 05/2019 - 01/2016
2	alpha-hydroxyglutarateIBA 03/2023 - 01/2023
2	pembrolizumabIBA 01/2023 - 01/2022
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 01/2021
2	Interleukin-7 (Interleukin 7)IBA 01/2022 - 09/2015
2	CopperIBA 05/2019 - 05/2018
2	Dexamethasone (Maxidex)FDA LinkGeneric 10/2017 - 09/2015
1	Vincristine (Oncovin)FDA LinkGeneric 11/2022
1	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2022
1	Methotrexate (Mexate)FDA LinkGeneric 11/2022
1	efineptakin alfaIBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021
1	GadoliniumIBA 10/2020
1	Alkylating AgentsIBA 09/2020
1	Adrenal Cortex Hormones (Corticosteroids)IBA 05/2019
1	Protein Subunit VaccinesIBA 01/2019
1	Proteasome Endopeptidase Complex (Proteasome)IBA 05/2018
1	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2018
1	P 11 (P-11)IBA 01/2018
1	DNA (Deoxyribonucleic Acid)IBA 01/2018

Therapy/Procedure

16	Therapeutics 05/2024 - 01/2016
12	Radiotherapy 05/2024 - 08/2015
6	Drug Therapy (Chemotherapy) 05/2024 - 01/2017
5	Lasers (Laser) 01/2022 - 01/2016
3	Immunotherapy 02/2024 - 01/2022
2	Craniospinal Irradiation 02/2024 - 01/2023
2	Chronotherapy 05/2022 - 01/2021
2	Adjuvant Chemotherapy 01/2022 - 01/2018
2	Laser Therapy (Surgery, Laser) 01/2022 - 01/2016
2	Aftercare (After-Treatment) 03/2021 - 04/2019
2	Chemoradiotherapy 05/2019 - 01/2016
1	Salvage Therapy 01/2021
1	Re-Irradiation 01/2018